Company intelligence / Profile preview

Neurochase

Bristol, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Neurochase is preparing to enter clinical trials in 2025 with its next-generation CNS delivery platform, enabling direct delivery of therapies such as gene therapy to brain targets via a proprietary convection enhanced micro-catheter system.

Therapeutic areas: OncologyNeurology
Modalities: DeviceGene therapyBiologic
Industry: Surgical Medical Devices

Partnerships

Vivolta

Beyond the preview

Go deeper on Neurochase.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurochase.

Explore the full profile